More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.59B
EPS
0.6
P/E ratio
--
Price to sales
3.42
Dividend yield
--
Beta
0.775516
Previous close
$18.51
Today's open
$19.29
Day's range
$18.27 - $19.77
52 week range
$12.89 - $28
show more
CEO
Franco Stevanato
Employees
5521
Headquarters
Piombino Dese, Padua
Exchange
New York Stock Exchange
Shares outstanding
302842536
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- #DiabetesTherapies--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism.
Business Wire • a day ago

Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Zacks Investment Research • Jun 3, 2026

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders' Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, t.
Business Wire • Jun 3, 2026

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • May 12, 2026

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 7, 2026

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions.
Business Wire • May 7, 2026

Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.11 per share a year ago.
Zacks Investment Research • May 7, 2026

Stevanato Group to Participate in Three Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chi.
Business Wire • May 4, 2026

Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Apr 30, 2026

Conestoga Capital SMid Cap Composite Q1 2026 Portfolio Holdings
The Conestoga SMid Cap Composite returned -10.24% net-of-fees in the first quarter, lagging the Russell 2500 Growth Index's return of -3.52%. RBC's performance was driven by continued strength in aerospace and defense, where demand remains robust and increasingly visible through a growing backlog. Despite a solid quarter, Repligen stock underperformed as investors focused on a more measured outlook and lingering concerns around end-market demand.
Seeking Alpha • Apr 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Stevanato Group S.p.A. commission-free¹. Build wealth for the long term using automated trading and transfers.